Cibus, Inc. (CBUS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cibus, Inc. on November 18, 2024. The filing reports a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of August Moretti as a member of the Board of Directors, effective November 18, 2024. Mr. Moretti will also serve as a member of the Board's Audit Committee.
Management Commentary and Governance Details
- Background: Mr. Moretti, 74, brings extensive experience as a former CFO for 4D Molecular Therapeutics, Inc., Assertio Therapeutics, Alexza Pharmaceuticals, and Alavita, Inc. He holds a B.A. in Economics from Princeton University and a J.D. from Harvard Law School.
- Compensation: Mr. Moretti will receive annual compensation pursuant to the Company's Non-Employee Director Compensation Policy. No specific dollar amounts are disclosed in this filing.
- Agreements: The Company entered into its standard form of indemnification agreement with Mr. Moretti. There are no arrangements or understandings between Mr. Moretti and other persons regarding his appointment.
Investor Verification Checklist
- Verify the specific annual compensation amounts for non-employee directors in the Company's Definitive Proxy Statement for the 2024 Annual Meeting of Stockholders.
- Review the composition of the Audit Committee to confirm Mr. Moretti's independence status under NASDAQ listing rules.
- Monitor future filings for any changes to the Board's committee assignments or additional director appointments.